[ET Net News Agency, 31 March 2020] Credit Suisse lowered its target price for
Sinopharm Group (01099) to HK$25.2 from HK$26.08 and maintained its "outperform" rating.
The research house said Sinopharm's FY2019 revenue beat due to better-than-expected
revenue growth in distribution and device segments. But its net profit was just in line,
partially due to higher-than-expected finance costs.
Credit Suisse increased its FY2020/21 revenue estimates by 4.3%/3.7% due to
better-than-expected segment results. Management continues to see recovery in business
segments and expects the impact to be limited to 1H. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
19.540 -0.180 (-0.913%) Research Report
31/03/2020 17:55
{I-bank focus}Credit Suisse cuts Sinopharm Group to HK$25.2
| Remark: | Real time quote last updated: 16/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |